[go: up one dir, main page]

HUS2200029I1 - Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik - Google Patents

Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik

Info

Publication number
HUS2200029I1
HUS2200029I1 HUS2200029C HUS2200029C HUS2200029I1 HU S2200029 I1 HUS2200029 I1 HU S2200029I1 HU S2200029 C HUS2200029 C HU S2200029C HU S2200029 C HUS2200029 C HU S2200029C HU S2200029 I1 HUS2200029 I1 HU S2200029I1
Authority
HU
Hungary
Prior art keywords
applications
preparations containing
containing conjugated
polysaccharide antigens
immunogenic preparations
Prior art date
Application number
HUS2200029C
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52630420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS2200029(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of HUS2200029I1 publication Critical patent/HUS2200029I1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HUS2200029C 2014-01-21 2022-06-09 Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik HUS2200029I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461929547P 2014-01-21 2014-01-21
EP15708580.4A EP3096785B1 (en) 2014-01-21 2015-01-15 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Publications (1)

Publication Number Publication Date
HUS2200029I1 true HUS2200029I1 (hu) 2022-07-28

Family

ID=52630420

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE15708580A HUE051728T2 (hu) 2014-01-21 2015-01-15 Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik
HUS2200029C HUS2200029I1 (hu) 2014-01-21 2022-06-09 Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik
HUS2200035C HUS2200035I1 (hu) 2014-01-21 2022-07-28 Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE15708580A HUE051728T2 (hu) 2014-01-21 2015-01-15 Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2200035C HUS2200035I1 (hu) 2014-01-21 2022-07-28 Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik

Country Status (28)

Country Link
US (1) US9492559B2 (hu)
EP (3) EP3096785B1 (hu)
JP (6) JP6335326B2 (hu)
KR (5) KR20230021167A (hu)
CN (6) CN110859957B (hu)
AR (3) AR099445A1 (hu)
AU (6) AU2015208821B2 (hu)
CA (3) CA3206112A1 (hu)
DK (1) DK3096785T3 (hu)
ES (1) ES2820824T3 (hu)
FR (2) FR22C1028I2 (hu)
HU (3) HUE051728T2 (hu)
IL (6) IL296681B2 (hu)
LU (2) LUC00268I2 (hu)
MX (4) MX379051B (hu)
NO (2) NO2022021I1 (hu)
NZ (5) NZ721943A (hu)
PE (2) PE20212335A1 (hu)
PH (2) PH12016501243B1 (hu)
PL (1) PL3096785T3 (hu)
PT (1) PT3096785T (hu)
RU (1) RU2771293C2 (hu)
SA (2) SA516371506B1 (hu)
SG (2) SG11201604728XA (hu)
SI (1) SI3096785T1 (hu)
TW (4) TWI679987B (hu)
WO (1) WO2015110941A2 (hu)
ZA (1) ZA201603925B (hu)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
DK1868645T3 (da) 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
SG11201500566XA (en) 2012-08-16 2015-04-29 Pfizer Glycoconjugation processes and compositions
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
CN110859957B (zh) 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN112336854B (zh) * 2014-01-21 2024-11-26 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
AU2016254693B2 (en) * 2015-04-28 2020-07-09 Biological E Limited Method for separation of protein and other impurities from microbial capsular polysaccharides
NZ736238A (en) * 2015-05-04 2022-07-01 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
KR20210027523A (ko) * 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) * 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
CN106110316A (zh) * 2016-06-27 2016-11-16 北京智飞绿竹生物制药有限公司 一种肺炎球菌结合物组合疫苗的制备方法
MY199342A (en) * 2016-08-05 2023-10-24 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI789357B (zh) * 2016-08-05 2023-01-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
JP2018042864A (ja) * 2016-09-15 2018-03-22 株式会社三洋物産 遊技機
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CN108144052A (zh) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 肺炎链球菌多糖-蛋白质缀合物及其制取方法和用途
CN110366428B (zh) * 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2018208844B2 (en) * 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
CN110225764A (zh) * 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
US11246918B2 (en) 2017-02-03 2022-02-15 Eva Barbara Schadeck Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
DK3585803T3 (da) * 2017-02-24 2025-12-15 Merck Sharp & Dohme Llc Formuleringer af pneumokokkal konjugatvaccine
AU2018225099B2 (en) * 2017-02-24 2024-08-22 Merck Sharp & Dohme Llc Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN118356485A (zh) 2017-06-10 2024-07-19 创赏公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
EP3668309A4 (en) * 2017-08-14 2021-06-09 University of Georgia Research Foundation, Inc. PROTEINS WITH PNEUMOCOCCK CAPSULE DEGRADING ACTIVITY AND METHOD OF USING
CN110996992A (zh) * 2017-08-16 2020-04-10 默沙东公司 肺炎球菌缀合物疫苗制剂
CA3074711A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065388A (zh) 2017-09-07 2020-04-24 默沙东公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
HRP20241185T1 (hr) 2017-09-07 2024-11-22 Merck Sharp & Dohme Llc Pneumokokni polisaharidi i njihova primjena u imunogenim konjugatima polisaharid-proteinski nosač
US12257295B2 (en) 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
SG11202005255PA (en) 2017-12-06 2020-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MY205174A (en) * 2018-02-05 2024-10-04 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN111757754B (zh) 2018-02-05 2024-07-05 赛诺菲巴斯德有限公司 多价肺炎球菌多糖-蛋白质缀合物组合物
KR20190121713A (ko) 2018-04-18 2019-10-28 에스케이바이오사이언스(주) 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
CN112543649A (zh) * 2018-07-04 2021-03-23 Vaxcyte公司 免疫原性缀合物的改进
WO2020009462A1 (ko) * 2018-07-06 2020-01-09 주식회사 유바이오로직스 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 폐렴구균에 의한 질환 예방 백신
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020058963A1 (en) 2018-09-23 2020-03-26 Biological E Limited Purified capsular polysaccharides of streptococcus pneumoniae
US11103567B2 (en) 2018-12-06 2021-08-31 Academia Sinica Glycoconjugate vaccines, preparation method and uses thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JOP20210148A1 (ar) 2018-12-19 2023-01-30 Merck Sharp & Dohme تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
WO2020152706A1 (en) * 2019-01-21 2020-07-30 Biological E Limited Multivalent pneumococcal conjugate vaccine compositions
WO2020157772A1 (en) * 2019-01-28 2020-08-06 Biological E Limited Multivalent pneumococcal polysaccharide-protein conjugate vaccine compositions
JP7239509B6 (ja) * 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
KR102754880B1 (ko) * 2019-05-28 2025-01-13 에스케이바이오사이언스(주) 스트렙토코커스 뉴모니애 혈청형 23f의 면역원성 접합체 제조방법
CA3148824A1 (en) * 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
EP4144365A4 (en) * 2020-05-01 2024-06-05 Sinocelltech Ltd. METHODS FOR IMPROVING THE IMMUNOGENERICITY OF PROTEIN/PEPTIDE ANTIGEN
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4243863A2 (en) 2020-11-10 2023-09-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
JP7207495B2 (ja) * 2021-02-05 2023-01-18 株式会社三洋物産 遊技機
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
CN115721709A (zh) * 2021-08-27 2023-03-03 康希诺生物股份公司 一种肺炎球菌结合疫苗制备方法
EP4522208A1 (en) 2022-05-11 2025-03-19 Pfizer Inc. Process for producing of vaccine formulations with preservatives
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105291A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
KR20250107930A (ko) 2022-11-22 2025-07-14 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
EP4626405A1 (en) 2022-12-01 2025-10-08 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
NZ249704A (en) 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
DE69324487T2 (de) 1992-05-06 1999-08-12 The President and Fellows of Harvard College, Cambridge, Mass. Rezeptorbindende region des diphtherietoxius
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
KR100376361B1 (ko) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DE69628418T2 (de) 1995-03-22 2004-04-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
EP0831894A1 (en) * 1995-06-07 1998-04-01 Alberta Research Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
JP4689044B2 (ja) 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
EP2261358B1 (en) 1998-12-23 2014-05-14 ID Biomedical Corporation of Quebec Novel streptococcus antigen
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
DE122009000054I1 (de) 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa Impfstoff gegen bakterielle antigene
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
HK1044484B (en) 1999-04-19 2005-07-29 Smithkline Beecham Biologicals S.A. Adjuvant composition containing saponin and immunostimulatory oligonucleotide
CO5200837A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
HK1046861A1 (zh) 1999-09-24 2003-01-30 Smithkline Beecham Biologicals S.A. 包括聚氧乙烯烷基酯或者醚以及至少一種非離子表面活性劑的佐劑
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
KR100927767B1 (ko) 2000-06-20 2009-11-20 아이디 바이오메디칼 코포레이션 스트렙토코커스 항원
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003054007A2 (en) 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
KR101052996B1 (ko) 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
KR20100018029A (ko) 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
DK1866342T3 (en) 2005-04-08 2019-01-28 Wyeth Llc SEPARATION OF POLLUTANTS CONTAMINATING FROM STREPTOCOCCUS PNEUMONIAE POLYSACCHARID BY PH-MANIPULATION
DK1868645T3 (da) * 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
BRPI0612655B1 (pt) * 2005-06-27 2021-06-15 Pfizer Ireland Pharmaceuticals Composição imunogênica
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101441368B1 (ko) * 2005-12-22 2014-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 폐렴구균 다당류 컨쥬게이트 백신
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
JP5260531B2 (ja) 2006-10-10 2013-08-14 ワイス・エルエルシー 肺炎連鎖球菌３型多糖体の精製
KR101500771B1 (ko) 2007-03-23 2015-03-18 와이어쓰 엘엘씨 스트렙토코커스 뉴모니아 협막 다당류를 제조하기 위한 단축 정제 방법
AU2008265767B2 (en) * 2007-06-20 2014-11-13 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
DK2167121T3 (en) * 2007-06-26 2015-11-23 Glaxosmithkline Biolog Sa A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater
CA2756398A1 (en) * 2009-03-24 2010-09-30 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
ES2552153T3 (es) * 2009-04-30 2015-11-26 Coley Pharmaceutical Group, Inc. Vacuna neumocócica y usos de la misma
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2011145108A2 (en) * 2010-05-15 2011-11-24 Serum Institute Of India Ltd. Purification of capsular polysaccharides
AR084158A1 (es) * 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
SG11201500566XA (en) * 2012-08-16 2015-04-29 Pfizer Glycoconjugation processes and compositions
PL2935299T3 (pl) 2012-12-20 2020-05-18 Pfizer Inc. Sposób glikokoniugacji
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
CN103495161B (zh) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
CN110859957B (zh) 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途

Also Published As

Publication number Publication date
CN114848805A (zh) 2022-08-05
LUC00274I2 (hu) 2025-05-12
MX379051B (es) 2025-03-11
CN110787290B (zh) 2024-06-04
AR099445A1 (es) 2016-07-27
BR112016015525A2 (pt) 2017-10-24
PE20212335A1 (es) 2021-12-16
KR20200108496A (ko) 2020-09-18
TWI682778B (zh) 2020-01-21
ZA201603925B (en) 2017-09-27
MX2021000523A (es) 2021-06-23
IL246853B (en) 2021-04-29
NO2022021I1 (no) 2022-06-09
NZ755770A (en) 2023-06-30
PL3096785T3 (pl) 2021-03-08
RU2687460C2 (ru) 2019-05-13
AU2015208821A1 (en) 2016-07-07
EP3607966A1 (en) 2020-02-12
IL282215B2 (en) 2023-02-01
MX2016009470A (es) 2017-01-18
NZ760783A (en) 2023-07-28
IL283058B (en) 2022-10-01
JP2017509656A (ja) 2017-04-06
CN106102770A (zh) 2016-11-09
AU2024201996A1 (en) 2024-05-16
AU2025237966A1 (en) 2025-10-16
AU2019204623B2 (en) 2021-04-29
KR20220080201A (ko) 2022-06-14
AU2015208821B2 (en) 2017-11-02
JP7579900B2 (ja) 2024-11-08
CA3170344C (en) 2023-08-29
JP6335326B2 (ja) 2018-05-30
IL312327B2 (en) 2026-02-01
AR130929A2 (es) 2025-01-29
SA520420930B1 (ar) 2024-01-09
CA3170344A1 (en) 2015-07-30
HUS2200035I1 (hu) 2022-08-28
AU2021206895B2 (en) 2024-02-22
NZ759686A (en) 2023-07-28
TWI679987B (zh) 2019-12-21
PH12021550318A1 (en) 2021-10-04
PH12016501243A1 (en) 2016-08-15
CA3206112A1 (en) 2015-07-30
AU2017268651A1 (en) 2017-12-21
AU2021206895C1 (en) 2024-07-25
LUC00268I2 (hu) 2025-04-25
CN110859957A (zh) 2020-03-06
RU2019112411A (ru) 2019-05-31
NO2022035I1 (no) 2022-08-04
IL282215B (en) 2022-10-01
AU2017268651B2 (en) 2019-08-01
TW201828978A (zh) 2018-08-16
IL296681B1 (en) 2024-05-01
SG11201604728XA (en) 2016-08-30
AR130928A2 (es) 2025-01-29
EP3616716A2 (en) 2020-03-04
HUE051728T2 (hu) 2021-03-29
RU2771293C2 (ru) 2022-04-29
SI3096785T1 (sl) 2020-12-31
SA516371506B1 (ar) 2021-06-01
TW202112392A (zh) 2021-04-01
WO2015110941A3 (en) 2015-11-26
CA2937186A1 (en) 2015-07-30
JP2023065429A (ja) 2023-05-12
TW201531299A (zh) 2015-08-16
CN110787290A (zh) 2020-02-14
RU2019112411A3 (hu) 2021-06-24
MX2021000522A (es) 2021-06-08
FR22C1028I2 (fr) 2025-01-03
RU2016129991A3 (hu) 2018-03-01
JP7227943B2 (ja) 2023-02-22
EP3096785A2 (en) 2016-11-30
RU2016129991A (ru) 2018-03-01
IL282215A (en) 2021-05-31
ES2820824T3 (es) 2021-04-22
IL283058A (en) 2021-06-30
JP2025020211A (ja) 2025-02-12
CN119303072A (zh) 2025-01-14
IL283058B2 (en) 2023-02-01
AU2019204623A1 (en) 2019-07-18
KR20160098507A (ko) 2016-08-18
DK3096785T3 (da) 2020-09-21
IL296681B2 (en) 2024-09-01
FR22C1028I1 (fr) 2022-09-09
IL270090B (en) 2021-05-31
JP7059095B2 (ja) 2022-04-25
MX2021000520A (es) 2021-06-08
PT3096785T (pt) 2020-10-13
KR20230021167A (ko) 2023-02-13
JP2025020213A (ja) 2025-02-12
JP2020164550A (ja) 2020-10-08
IL312327A (en) 2024-06-01
US20150202309A1 (en) 2015-07-23
FR22C1040I1 (fr) 2022-09-09
TWI748810B (zh) 2021-12-01
CA2937186C (en) 2022-11-01
EP3096785B1 (en) 2020-09-09
IL246853A0 (en) 2016-08-31
CN114887048A (zh) 2022-08-12
AU2021206895A1 (en) 2021-08-12
PH12016501243B1 (en) 2021-10-29
JP2018135374A (ja) 2018-08-30
KR20240146095A (ko) 2024-10-07
CN110859957B (zh) 2024-04-12
TW202003024A (zh) 2020-01-16
EP3616716A3 (en) 2020-05-06
PE20161095A1 (es) 2016-10-26
NZ755769A (en) 2023-06-30
WO2015110941A2 (en) 2015-07-30
KR102157200B1 (ko) 2020-09-21
SG10201803187VA (en) 2018-05-30
NZ721943A (en) 2022-07-01
US9492559B2 (en) 2016-11-15
CN106102770B (zh) 2022-03-22
IL296681A (en) 2022-11-01
TWI715285B (zh) 2021-01-01
IL312327B1 (en) 2025-10-01
CN114887048B (zh) 2025-09-05

Similar Documents

Publication Publication Date Title
HUS2200035I1 (hu) Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik
IL284348A (en) Hiv pre-immunization and immunotherapy
HUE061247T2 (hu) Termékek és készítmények
HUE055838T2 (hu) Amfifil poliszacharid-származékok és azokat tartalmazó készítmények
HUE053366T2 (hu) Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
HUE056677T2 (hu) Anti-tim-3 ellenanyagok és készítmények
IL261963A (en) Antibodies, pharmaceutical compositions and methods
HUE054103T2 (hu) Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
HUE047784T2 (hu) Anti-TIM3 antitestek és alkalmazási eljárások
HUE053332T2 (hu) Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
HUE045307T2 (hu) EGFRVIII-ellenes antitestek és alkalmazásaik
HUE045216T2 (hu) Anti-CD79B antitestek és alkalmazási eljárások
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
HUE059338T2 (hu) Ellenanyagok, alkalmazások és eljárások
IL246837B (en) Antibodies, pharmaceutical compositions and uses thereof
HUE050028T2 (hu) Neuroaktív szteroidok, készítmények és alkalmazásuk
HUE055553T2 (hu) Streptococcus pneumoniae kapszulás poliszacharidok és azok konjugátumai
HUE052771T2 (hu) C10orf54 elleni antitestek és alkalmazásuk
HUE061253T2 (hu) Antitestek OX40 ellen és azok felhasználásai
HUE053619T2 (hu) Anti-CD123 antitestek és konjugátumok és ezek származékai
LT3137114T (lt) Anti-ptk7 antikūnų ir vaistų konjugatai
HUE055408T2 (hu) Streptococcus pneumoniae kapszuláris poliszacharidok és konjugátumaik
EP3413926A4 (en) HIV VACCINATION AND IMMUNOTHERAPY
HUE055020T2 (hu) Prosztata-antigén szabványok és azok felhasználása
EP3316863A4 (en) DIRECTED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF